Madeleine Caven1, Amy Malaguti2, Emma Robinson3, Emma Fletcher4, John F Dillon3. 1. School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom. Electronic address: mzcaven@dundee.ac.uk. 2. School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom; Public Health Directorate, NHS Tayside, Kings Cross Hospital, Dundee, Scotland, United Kingdom; School of Social Sciences (Psychology), University of Dundee, Dundee, Scotland, United Kingdom; Adult Psychological Therapies Service, NHS Tayside, 15 Dudhope Terrace, Dundee, Scotland, United Kingdom. 3. School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom; Department of Gastroenterology, NHS Tayside, Ninewells Hospital, Dundee, Scotland, United Kingdom. 4. School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom; Public Health Directorate, NHS Tayside, Kings Cross Hospital, Dundee, Scotland, United Kingdom.
Abstract
BACKGROUND: A systematic review was conducted to determine the impact of Hepatitis C (HCV) treatment on substance use behaviour in people who inject drugs (PWID). METHODS: A search for peer reviewed journal articles from 1991 to present day was conducted using the following databases: PubMed, EMBASE, CINAHL and PsycINFO. Studies were appraised against the following inclusion criteria: recruitment of PWID for HCV treatment (either interferon alpha or direct acting antivirals based); measurement of behavioural change in relation to drug use; studies published in English. RESULTS: Five studies investigating the impact of HCV treatment on behavioural change in relation to drug use amongst PWID were identified. Studies investigated the impact of HCV treatment on past month injecting drug use (four studies), injecting frequency (two studies), needle and syringe borrowing (two studies) and injecting equipment sharing (three studies). Three of the four studies assessing impact of treatment on past month injecting frequency found treatment significantly reduced the odds of participants reporting past month injecting at follow up. One study found that there was significant reduction in weekly injecting frequency between enrolment, treatment and follow up. No association was found between treatment engagement and needle and syringe borrowing. Two out of three studies reported a significant decrease in injecting equipment sharing between enrolment, treatment and follow up. CONCLUSIONS: Comparison and synthesis of results was challenging due to heterogeneity between studies. Moreover, four out of the five selected studies were conducted during the interferon era of treatment, possibly limiting the generalisability of the current review's results to the new DAA treatment era. However, it is likely that engaging in treatment has a positive impact upon patients' injecting drug use and injection equipment sharing behaviour. This raises the possibility that this may be an opportune time for further harm reduction measures.
BACKGROUND: A systematic review was conducted to determine the impact of Hepatitis C (HCV) treatment on substance use behaviour in people who inject drugs (PWID). METHODS: A search for peer reviewed journal articles from 1991 to present day was conducted using the following databases: PubMed, EMBASE, CINAHL and PsycINFO. Studies were appraised against the following inclusion criteria: recruitment of PWID for HCV treatment (either interferon alpha or direct acting antivirals based); measurement of behavioural change in relation to drug use; studies published in English. RESULTS: Five studies investigating the impact of HCV treatment on behavioural change in relation to drug use amongst PWID were identified. Studies investigated the impact of HCV treatment on past month injecting drug use (four studies), injecting frequency (two studies), needle and syringe borrowing (two studies) and injecting equipment sharing (three studies). Three of the four studies assessing impact of treatment on past month injecting frequency found treatment significantly reduced the odds of participants reporting past month injecting at follow up. One study found that there was significant reduction in weekly injecting frequency between enrolment, treatment and follow up. No association was found between treatment engagement and needle and syringe borrowing. Two out of three studies reported a significant decrease in injecting equipment sharing between enrolment, treatment and follow up. CONCLUSIONS: Comparison and synthesis of results was challenging due to heterogeneity between studies. Moreover, four out of the five selected studies were conducted during the interferon era of treatment, possibly limiting the generalisability of the current review's results to the new DAA treatment era. However, it is likely that engaging in treatment has a positive impact upon patients' injecting drug use and injection equipment sharing behaviour. This raises the possibility that this may be an opportune time for further harm reduction measures.
Authors: Xinyi Jiang; Scott Martin Vouri; Vakaramoko Diaby; Weihsuan Lo-Ciganic; Robert Parker; Haesuk Park Journal: J Manag Care Spec Pharm Date: 2021-10
Authors: Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321
Authors: Jason Grebely; Phillip Read; Evan B Cunningham; Martin Weltman; Gail V Matthews; Adrian Dunlop; Mark Montebello; Marianne Martinello; Rosie Gilliver; Philippa Marks; Tanya L Applegate; Gregory J Dore Journal: Health Sci Rep Date: 2020-03-15
Authors: Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin Journal: Lancet Date: 2019-10-23 Impact factor: 79.321
Authors: Kristi Hill; Laura Nussdorf; Julia D Mount; Rachel Silk; Chloe Gross; David Sternberg; Phyllis Bijole; Miriam Jones; Randy Kier; Dana Mccullough; Poonam Mathur; Shyam Kottilil; Henry Masur; Sarah Kattakuzhy; Elana S Rosenthal Journal: J Addict Med Date: 2022 Jan-Feb 01 Impact factor: 3.702
Authors: Eric Tatara; Alexander Gutfraind; Nicholson T Collier; Desarae Echevarria; Scott J Cotler; Marian E Major; Jonathan Ozik; Harel Dahari; Basmattee Boodram Journal: PLoS One Date: 2022-03-10 Impact factor: 3.240